News and Trends 20 Aug 2019
Nabriva Therapeutics Gets FDA Green Light for Pneumonia Antibiotic
The US FDA has approved Nabriva Therapeutics’ Xenleta for treating community-acquired bacterial pneumonia, the first in a new class of…
Nabriva Therapeutics
- Latest Posts
News and Trends 23 May 2018
Another Pneumonia Antibiotic is Close to Treating Patients
Nabriva Therapeutics has obtained positive Phase III results for its antibiotic lefamulin and plans to seek FDA approval for the…
News and Trends 13 Nov 2017
World Antibiotic Awareness Week: Here are Biotech’s Top 5 Strategies to Overcome Resistance
This week marks the WHO's World Antibiotic Awareness Week. We had a look at some of the best work being done…
More News! 18 Sep 2017
Austrian Biotech Scores a Phase III Win in the Fight Against Antibiotic Resistance
The novel antibiotic lefamulin brought home late-stage success to Nabriva by proving itself to be on par with the standard treatment…
ADVERTISEMENT
Interview 18 Sep 2017
David Chiswell: “We are getting close to the best way of making antibodies”
We interviewed David Chiswell, a pioneer in the development of therapeutic antibodies and now the CEO of Kymab, which he…
Infographics 21 Feb 2017
Infographic: The Biggest Biotech Company in Each European Country
We had a look into European biotech and created a map with the biggest biotech companies in each country, according…
News and Trends 12 Sep 2016
Grüßgott, get to Meet 9 exciting Biotechs from Vienna
Classical music, the Danube, Schnitzel, and apple strüdel - a typical combination of Vienna. The city has also been at…
News and Trends 27 Sep 2015
What Happened this Week? Human Embryos Back on the Bench, Stem Cells in your Heart and New Antibiotics
Monday: Nabriva Therapeutics launched its $100M IPO on the NASDAQ to develop new antibiotics Tuesday: the Francis Crick Institute announced its application…
